The Golden Helix Foundation is an international non-profit research organization (registered London-based UK charity), established in 2003, aiming to advance interdisciplinary research and education in the area of Genomic and Personalized Medicine. The Golden Helix Foundation aims to promote the development of research and the transfer and communication of knowledge from researchers and scientists in the wider scientific community through collaborative projects and conferences in the field of pharmacogenomics and personalized medicine.
In particular, the aims of the Golden Helix Foundation are to:
- Engage in research projects in the field of Genomic and Precision Medicine,
- Partner with international organizations and academic entities in the field of precision medicine
- Provide training & educational courses in the field of Genomic Medicine,
- Organize conferences in the field of Genomic Medicine, and
- Act as an umbrella organization for multinational collaborative efforts in the area of Genomic and Precision Medicine.
The Golden Helix Foundation headquarters are located in London (United Kingdom) and its activities are coordinated by 3 regional Centers in Athens (Greece; South Europe and Mediterranean), Al-Ain (United Arab Emirates; Middle East) and Kuala Lumpur (Malaysia; Asia-Pacific).
Department of Pharmacy, University of Patras (UPAT)
The Department of Pharmacy, University of Patras is housed in a new 20.000 m2 building. The Laboratory of Pharmacogenomics and Individualized Therapy at the Department of Pharmacy has modern infrastructure, where several projects on genetics of human disorders, pharmacogenomics and genomics are being implemented. The group consists of over 20 researchers, from faculty members to graduate students and has long experience in managing national and international grants, particularly from the European Commission. Also, the laboratory of Pharmacogenomics and Individualized Therapy at the Department of Pharmacy has been awarded a 3M EUR FP7-REGPOT-2011-1 grant in the field of Structural Biology (SEE-DRUG, Proj. no 285950) for its “excellence in research and of its leadership potential”, further outlining the excellence of the research entities and their experience in managing big international grants. Lastly, the laboratory of Pharmacogenomics and Individualized Therapy is a core partner of the Ubiquitous Pharmacogenomics (U-PGx; H2020-668353) project, a 15M EUR project funded by the European Commission, aiming to implement pre-emptive pharmacogenomics in the clinical setting.